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Chemical conjugation of fatty acids to antibodies generates lipid-modified molecules which have found use in the targeting of liposome-mediated 
drug delivery and in liposome-based immunoassays. Alternatively, bacterial expression of antibodies as single-chain Fv fragments fused to lipoprotein 
signal peptide and N-terminal sequence leads to in vivo enzymatic addition of a single glycerolipid group at the N-terminus of the molecule. This 
lipid-modification converts the antibody from a soluble protein into a functional membrane-bound molecule. These biosynthetically lipid-tagged 
antibodies may prove useful for immobilization of antibodies to membranes in various biotechnological pplications. 
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1. Introduction 
In several biotechnological applications, e.g. in the 
targeting of liposomal drug delivery [14], in liposome- 
based immunoassays [5] and in the design of biomimetic 
sensors [6,7] lipid-modified antibody molecules have 
been immobilized on planar and liposomal phospholipid 
membranes. Chemical in vitro conjugation to fatty acids 
or other lipid moieties is used to convert normally solu- 
ble antibodies into a form which can be inserted into the 
membrane. In addition to endowing antibodies with 
membrane anchors, chemical lipid modification of pro- 
teins has been used to increase immunogenicity of pep- 
tides and proteins in the design of improved vaccines 
[8-lo]. Furthermore, ‘hydrophobization’ by chemical 
conjugation to lipids has been used to increase the mem- 
brane permeation [l l] and stability [12] of proteins. The 
chemical derivatizations most commonly involve direct 
coupling of fatty acyl groups to appropriately exposed 
sulphhydryl and amino groups in the protein molecule 
[13,14]. Subjecting antibodies and other polypeptides to 
this treatment may lead to loss or decrease in the activity 
of the labeled molecule due to the denaturation or 
through indirect effects the fatty acid moieties impart on 
the function of the molecule. In chemical coupling proce- 
dures the product often shows heterogeneity in terms of 
number and location of lipid moieties. Biotin-avidin 
technology has been used to link biotinylated antibodies 
to biotinylated liposomes via an avidin (or streptavidin) 
linker [15]. The use of this approach, however, also re- 
quires chemical derivatization of the antibody (i.e. bioti- 
nylation) and the presence of an additional protein layer 
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of (strept)avidin may limit the general usefulness of this 
approach. 
Despite the above-mentioned limitations of the chemi- 
cal lipid-modification, the ability of membrane-anchored 
antibodies to provide liposomes with binding specificity 
for delivery of liposome-encased drugs, DNA and imag- 
ing agents and for the use of immobilized liposomes in 
diagnostic applications has been demonstrated [l-5]. 
Here we discuss the biochemical background and future 
prospects for an improved methodology for the produc- 
tion of lipid-tagged antibodies by use of genetic engineer- 
ing. 
2. In Volvo lipid-tagging of bacterial lipoproteins 
Bacterial lipoproteins are a diverse group of proteins 
which share in common a particular lipid modification 
at the N-terminal cysteine residue [16]. The covalently 
linked lipid moiety consists of two fatty acids linked by 
ester bonds and one fatty acid linked by an amide bond 
to glycerylcysteinyl [17] (see Fig. lb). This lipid group is 
very hydrophobic and anchors the protein to the mem- 
brane [18,19]. The details of the biosynthesis of lipopro- 
teins have been elucidated with the prototype lipopro- 
tein, the lpp lipoprotein of Escherichiu coli [18-211. Lpp 
is first synthesized as a signal peptide-containing precur- 
sor to which a diacylglyceride is added at the cysteine 
residue which later will become the N-terminus of the 
mature lipoprotein. The signal peptide is cleaved off by 
a lipoprotein-specific signal peptidase whereafter the 
newly exposed amino group is acylated and the mature 
Lpp is translocated to the outer membrane [20]. The 
molecular determinants responsible for the lipid modifi- 
cation and targeting of Lpp have been localized to the 
signal peptide and a short amino-terminal stretch of Lpp 
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[18]. This was demonstrated by the lipid modification, 
correct processing and transport to the outer membrane 
of a hybrid protein, lipo-/I-lactamase containing the sig- 
nal peptide and nine N-terminal amino acids of the ma- 
ture Lpp polypeptide fused to a soluble periplasmic pro- 
tein, /3-lactamase [ 181. Importantly, the amino-terminal 
sequence of lipo-/?-lactamase f atures no obvious hydro- 
phobic character and it appears that the lipid moiety 
alone tethers the hybrid protein to the inner leaflet of the 
outer membrane [18,221. 
Interestingly, the sorting of Lpp to the outer mem- 
brane (as opposed to inner membrane) is strongly af- 
fected by the identity of the second amino acid residue, 
next to lipid-modified cysteine as introduction of nega- 
tively-charged aspartate (but not of any other amino 
acid) leads to inner membrane localization [ 191. 
3. Genetically lipid-modified antibodies 
The deciphering of the molecular details of bacterial 
lipoprotein processing has set the stage for the rational 
design and bacterial expression of lipid-tagged proteins 
of biotechnological interest. To date, single-chain anti- 
bodies [23] and peptide antigens [24] have been produced 
using this approach. In principle any soluble protein 
which can be expressed as functional in E. coli can be 
produced as a lipoprotein fusion. Minimally these fusion 
proteins contain the lipoprotein signal peptide and only 
a few amino acids derived from lpp or other bacterial 
lipoprotein (see Fig. 1). The product will carry an amino- 
terminal cysteine residue decorated by the glycerolipid 
moiety, which anchors the protein to the bacterial mem- 
brane in situ and facilitates the insertion of the purified 
product to reconstituted liposomal or planar phospho- 
lipid membranes. 
Recently, we demonstrated functional expression in E. 
coli of an anti-2-phenyloxazolone antibody single-chain 
Fv fragment as a lipoprotein fusion [23]. This hybrid 
antibody displayed all major features of a membrane 
protein: it was cell-bound and co-purified with the outer 
membrane fraction, was released into solution only in 
the presence of detergents, partitioned into the Triton 
X-l 14 detergent phase in temperature-induced phase 
separation, and spontaneously and quantitatively associ- 
ated with liposomes upon removal of detergent [23]. 
These features of the lipid-tagged antibody were in strik- 
ing contrast to those of its soluble counterpart which was 
secreted into the periplasm by using the pelB signal pep- 
tide [23,25]. The different behaviour of the two antibody 
molecules was assigned to the presence of the covalent 
lipid modification, demonstrated by metabolic incorpo- 
ration of radiolabeled palmitic acid into the lipoprotein 
fusion antibody [23]. In terms of hapten (2-phenyloxa- 
zolone)-binding activity and specificity the two antibod- 
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Fig. 1. Outline of the lipoprotein fusion antibody (a) and of the N- 
terminal covalent lipid modification (b). 
antibody was active both in the detergent-solubilized 
state and in sonicated bacterial membrane vesicles. 
Whereas crude membrane-bound and solubilized ma- 
terial may be used for preliminary testing, detailed exper- 
iments and immunoliposome applications would need 
highly purified material. To facilitate rapid purification 
of the lipoprotein fusion antibodies we engineered six 
histidines to the C-terminus to serve as an affinity tag in 
immobilized metal chelation chromatography (Fig. la). 
Immunoliposomes prepared from the purified antibody 
and phospholipids display hapten-binding activity as 
shown by ELISA and by surface plasmon resonance 
measurements (Fig. 2) (M.-L.L., K. Alfthan and K.K., 
manuscript in preparation). In the latter method, associ- 
ation and dissociation of sample molecules in a layer of 
dextran-immobilized ligand give rise to changes in the 
refractive index, which is monitored in real time [26]. 
Immunoliposomes display markedly slower dissociation 
from the immobilized hapten than the soluble antibody 
due to multivalent binding as there are many antibody 
molecules per liposome (Fig. 2, M.-L.L. and K.K., un- 
published). This finding underscores the potential of im- 
munoliposomes to significantly strengthen the binding 
between the antibody and the antigen. 
Francisco and coworkers recently demonstrated that 
a fusion construct which contains the lipoprotein signal 
sequence and nine N-terminal amino acids followed by 
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Fig. 2. Binding (association and dissociation) of immunoliposomes 
(open squares) and the soluble antibody (solid squares) to immobilized 
hapten as measured by surface plamon resonance (BIAcore, Pharmacia 
Biosensors AB). Note the different scales in the Y-axes for the immu- 
noliposomes (left) and for the free antibody (right). 
amino acids 45-159 of the outer membrane protein 
OmpA can be used to express single-chain antibodies 
and other proteins on the bacterial cell surface [22,271. 
The lipoprotein part targets the protein to the outer 
membrane whereas the transmembrane OmpA part is 
used to obtain the correct topological orientation of the 
protein on the outer surface [22,27]. While this approach 
may prove useful in the screening of surface displayed 
antibodies and in catalytic and other biotechnological 
applications (e.g. as whole-cell absorbents) [28], the po- 
tential of these transmembrane hybrid antibodies for im- 
munoliposome-based applications has not been evalu- 
ated. 
4. Future prospects 
In comparison with the available chemical conjuga- 
tion methods for the production of lipid-modified pro- 
teins, bacterial expression as a lipoprotein fusion has 
several advantages. The product is labeled stoichiometri- 
tally and at a defined location. The single glycerolipid 
moiety provides sufficient hydrophobicity to anchor the 
lipoprotein fusion protein to phospholipid membrane in 
a stable and oriented manner. Use of bacterial expression 
may prove more economical in the scaled-up production 
of lipid-tagged molecules and may provide more flexibil- 
ity as further modifications can be engineered relatively 
easily into the molecule. In addition, the recent progress 
in the surface display technology has dramatically sim- 
plified the isolation of antibodies with desired properties 
[29]. The conversion of the isolated antibody fragments 
into a lipid-tagged form would then require only the 
transfer of the antibody coding cassette from the phage 
display vector into an expression vector which harbours 
the lipoprotein elements. 
Apart from the use of lipid-modified antibodies in 
immunoliposome technology, biosynthetic lipid-tagging 
may provide new tools for two-dimensional crystalliza- 
tion of proteins into lipid membranes for structural anal- 
ysis [30] and for the development of biosensors [6,7,31]. 
In this respect, the presence of a single lipid anchor in a 
defined location in lipoprotein fusion polypeptides in 
contrast to chemically modified molecules is significant 
as it may facilitate oriented, high-density immobilization 
to lipid bilayers. 
The biosynthetic lipid-tagging concept as based on 
bacterial lipoprotein modification might be extended to 
eukaryotic expression systems by taking advantage of 
the structural determinants responsible for the en- 
dogenously operating eukaryotic lipid modifications, in 
particular the C-terminal glycosyl-phosphatidylinositol 
anchor [32]. This would facilitate the use of eukaryotic 
expression systems to produce more complex and glyco- 
sylated polypeptides like whole antibodies in a lipid- 
tagged form. 
In conclusion, bacterial expression of antibodies and 
other polypeptides as lipoprotein fusions results in the 
formation of a lipid tag at the amino terminus. This tag 
can be used to immobilize the functional polypeptide to 
phospholipid membranes for diverse biotechnological 
applications. 
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